Biotronik targets FDA approval with stent trial

Biotronik has implanted its first Pulsar-18 stent in an IDE study--courtesy of Biotronik

Biotronik has kicked off a multi-center investigational device trial for its Pulsar-18, targeting U.S. approval for its self-expanding device.

The device is designed for the superficial femoral artery, expanding into the vessel to treat femoral disease. The study--enrolling patients in the U.S., Canada and Europe--will evaluate the safety and efficacy of the stents families in treating peripheral arterial disease, seeking 12-month primary patency and 30-day and 12-month freedom from major adverse events.

A previous European study found a 12-month primary patency of 81.4% and a 12-month freedom from target lesion revascularization of 89.3%, positive results Biotronik hopes to replicate as it seeks FDA approval for its vascular devices.

Biotronik touts Pulsar-18's compatibility with a 4-French (4F) sheath system, which investigator Carlos Mena of Yale University Medical Center said makes the device impressively versatile. "Performing an entire procedure through a 4F sheath can reduce the risk of patient bleeding and allow them to ambulate more quickly," Mena said in a statement.

The stent is the next generation of the market-leading Astron Pulsar, and Biotronik launched the device overseas in 2010. 

- read Biotronik's release

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.